|
||||||
|
 | |
| |
| Expression of this gene in the resistant group across all datasets and cell types |
| Significant ligand-receptor pairs related to this gene (This gene does not contain this module) |
| |
| |
| |
| Acts as a transcription factor (This gene does not contain this module) |
|
Gene: TPT1 |
Summary for TPT1 |
| Gene information | Gene symbol | TPT1 | Ensembl ID | ENSG00000133112 |
| Entrez ID | 7178 | |
| Gene name | tumor protein, translationally-controlled 1 | |
| Synonyms | fortilin|TCTP | |
| Gene type | protein_coding | |
| UniProtAcc | P13693 |
Top |
Dataset with differentially expressed gene: TPT1 |
 Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group. |
| Dataset | Source | Tissue | Cancer type level1 | Cancer type level2 | Drug type | Regimen | Timepoint | Cell type | avg_log2FC | p_val_adj |
GSE186960 | Panc1 cell line | Cell line | Pancreatic cancer | Pancreatic ductal adenocarcinoma (PDAC) | Chemotherapy | gemcitabine | NA | Malignant cells | 0.754497 | 0.00e+00 |
GSE163836 | FCIBC02 cell line | Cell line | Breast cancer | Inflammatory breast cancer | Chemotherapy | paclitaxel | NA | Malignant cells | 1.31244 | 0.00e+00 |
GSE169246_PacBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | post | cDCs | 0.556492 | 7.99e-24 |
GSE169246_PacBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | post | Plasma cells | 0.417194 | 1.10e-07 |
GSE169246_PacBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | post | B cells | 0.309704 | 0.00e+00 |
GSE169246_PacBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | pre | cDCs | 0.612102 | 2.92e-26 |
GSE169246_PacBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | pre | Mono/Macro | 0.285719 | 0.00e+00 |
GSE169246_PacTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | post | Plasma cells | -0.428364 | 5.48e-10 |
GSE169246_PacTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | pre | Plasma cells | 0.871311 | 0.00e+00 |
GSE169246_PacTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | pre | Mono/Macro | 0.272578 | 1.19e-05 |
GSE169246_PacTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | pre | CD4+ T cells | -0.347332 | 0.00e+00 |
GSE153697 | patients | Bone marrow aspirate | Acute lymphoblastic leukemia | Relapsed B-cell acute lymphoblastic leukemia (B-ALL) | Immunotherapy | anti-CD19 CAR-T | NA | Malignant cells | -0.341683 | 7.56e-21 |
GSE169246_PacAteTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Immunotherapy | atezolizumab + paclitaxel | post | Plasma cells | -0.559764 | 1.87e-05 |
GSE169246_PacAteTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Immunotherapy | atezolizumab + paclitaxel | post | Mono/Macro | -0.507861 | 3.03e-10 |
GSE169246_PacAteTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Immunotherapy | atezolizumab + paclitaxel | post | CD8+ T cells | 0.419379 | 0.00e+00 |
GSE169246_PacAteTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Immunotherapy | atezolizumab + paclitaxel | pre | CD8+ T cells | 0.477174 | 0.00e+00 |
GSE169246_PacAteTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Immunotherapy | atezolizumab + paclitaxel | pre | Mono/Macro | 0.435462 | 9.25e-34 |
GSE197268_Axi-cel | patients | Peripheral blood mononuclear cells | Acute lymphoblastic leukemia | Large B-cell acute lymphoblastic leukemia (B-ALL) | Immunotherapy | axi-cel (CAR-T) | post | CD8+ T cells | -0.294227 | 0.00e+00 |
GSE197268_Axi-cel | patients | Peripheral blood mononuclear cells | Acute lymphoblastic leukemia | Large B-cell acute lymphoblastic leukemia (B-ALL) | Immunotherapy | axi-cel (CAR-T) | post | Progenitors | 0.408435 | 1.73e-02 |
GSE164551 | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Immunotherapy | CAR-T | NA | Erythrocytes | -0.717197 | 2.03e-28 |
GSE164551 | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Immunotherapy | CAR-T | NA | NK cells | 0.645497 | 1.73e-02 |
PMID34715028 | patients | Tumor tissue | Kidney cancer | Clear cell renal cell carcinoma (ccRCC) | Immunotherapy | nivolumab | post | CD4+ T cells | 0.335858 | 1.39e-21 |
GSE164237 | patients | Peripheral blood mononuclear cells | Melanoma | Advanced stages of melanoma | Immunotherapy | pembrolizumab | post | CD8+ T cells | 0.299872 | 0.00e+00 |
GSE207422_Sin | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | CD8+ T cells | -0.329149 | 2.08e-16 |
GSE207422_Sin | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | Mono/Macro | -0.469543 | 1.71e-12 |
GSE207422_Tor | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | Neutrophils | 0.259369 | 1.19e-04 |
GSE207422_Tor | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | B cells | 0.755702 | 1.13e-12 |
GSE189460 | patients | Bone marrow aspirate | Multiple myeloma | Multiple myeloma (MM) | Targeted therapy | bortezomib + melphalan + prednisolone | pre | Erythrocytes | -0.338402 | 5.37e-21 |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | carfilzomib + dexamethasone | post | Mono/Macro | -0.491324 | 0.00e+00 |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | carfilzomib + dexamethasone | post | Malignant cells | 0.687891 | 6.10e-41 |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | carfilzomib + dexamethasone | post | cDCs | -0.776158 | 9.83e-08 |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | carfilzomib + dexamethasone | post | B cells | -0.57829 | 8.48e-03 |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | carfilzomib + dexamethasone | post | NK cells | -0.885129 | 0.00e+00 |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | carfilzomib + dexamethasone | post | CD8+ T cells | -0.603492 | 0.00e+00 |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | carfilzomib + dexamethasone | pre | Mono/Macro | 0.475636 | 9.81e-45 |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | carfilzomib + dexamethasone | pre | Malignant cells | -0.454368 | 3.93e-39 |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | carfilzomib + dexamethasone | pre | NK cells | -0.534329 | 2.75e-14 |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | carfilzomib + dexamethasone | pre | CD8+ T cells | 0.503549 | 0.00e+00 |
GSE161195 | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone) | post | Malignant cells | -0.470237 | 0.00e+00 |
GSE161195 | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone) | pre | Malignant cells | -0.485539 | 0.00e+00 |
GSE168668 | LNCaP cell line | Cell line | Prostate cancer | Prostate cancer | Targeted therapy | enzalutamide | NA | Malignant cells | -0.450568 | 0.00e+00 |
GSE149214 | PC9 cell line | Cell line | Lung cancer | EGFR-mutated non-small cell lung cancer (NSCLC) | Targeted therapy | erlotinib | NA | Malignant cells | -0.291907 | 2.62e-21 |
GSE162117 | patients | Peripheral blood mononuclear cells | Acute myeloid leukemia | Tefractory acute myeloid leukemia (AML) | Targeted therapy | ficlatuzumab | post | Malignant cells | -0.319491 | 0.00e+00 |
GSE162117 | patients | Peripheral blood mononuclear cells | Acute myeloid leukemia | Tefractory acute myeloid leukemia (AML) | Targeted therapy | ficlatuzumab | post | CD8+ T cells | -0.483821 | 4.45e-16 |
GSE162117 | patients | Peripheral blood mononuclear cells | Acute myeloid leukemia | Tefractory acute myeloid leukemia (AML) | Targeted therapy | ficlatuzumab | post | NK cells | -0.46841 | 5.89e-13 |
GSE162117 | patients | Peripheral blood mononuclear cells | Acute myeloid leukemia | Tefractory acute myeloid leukemia (AML) | Targeted therapy | ficlatuzumab | post | CD4+ T cells | -0.611936 | 0.00e+00 |
GSE162117 | patients | Peripheral blood mononuclear cells | Acute myeloid leukemia | Tefractory acute myeloid leukemia (AML) | Targeted therapy | ficlatuzumab | post | pDCs | -0.795059 | 2.40e-05 |
GSE162117 | patients | Peripheral blood mononuclear cells | Acute myeloid leukemia | Tefractory acute myeloid leukemia (AML) | Targeted therapy | ficlatuzumab | post | cDCs | -0.76398 | 0.00e+00 |
GSE162117 | patients | Peripheral blood mononuclear cells | Acute myeloid leukemia | Tefractory acute myeloid leukemia (AML) | Targeted therapy | ficlatuzumab | pre | cDCs | -0.577378 | 3.69e-07 |
GSE199333 | patients | Bone marrow aspirate | Acute myeloid leukemia | Primary FLT3-ITD-mutated acute myeloid leukemia (AML) | Targeted therapy | gilteritinib | post | CD8+ T cells | 0.653515 | 0.00e+00 |
GSE199333 | patients | Bone marrow aspirate | Acute myeloid leukemia | Primary FLT3-ITD-mutated acute myeloid leukemia (AML) | Targeted therapy | gilteritinib | post | Malignant cells | 0.359989 | 0.00e+00 |
GSE199333 | patients | Bone marrow aspirate | Acute myeloid leukemia | Primary FLT3-ITD-mutated acute myeloid leukemia (AML) | Targeted therapy | gilteritinib | pre | B cells | -1.0261 | 6.89e-08 |
GSE199333 | patients | Bone marrow aspirate | Acute myeloid leukemia | Primary FLT3-ITD-mutated acute myeloid leukemia (AML) | Targeted therapy | gilteritinib | pre | CD8+ T cells | 0.472313 | 4.23e-24 |
GSE111014 | patients | Peripheral blood mononuclear cells | Chronic lymphocytic leukemia | Chronic lymphocytic leukemia (CLL) | Targeted therapy | ibrutinib | post | CD8+ T cells | -0.356966 | 1.19e-06 |
GSE111014 | patients | Peripheral blood mononuclear cells | Chronic lymphocytic leukemia | Chronic lymphocytic leukemia (CLL) | Targeted therapy | ibrutinib | post | Malignant cells | -0.276284 | 1.83e-07 |
GSE111014 | patients | Peripheral blood mononuclear cells | Chronic lymphocytic leukemia | Chronic lymphocytic leukemia (CLL) | Targeted therapy | ibrutinib | post | NK cells | -0.314008 | 2.34e-03 |
GSE111014 | patients | Peripheral blood mononuclear cells | Chronic lymphocytic leukemia | Chronic lymphocytic leukemia (CLL) | Targeted therapy | ibrutinib | pre | CD4+ T cells | -0.978597 | 3.55e-20 |
GSE111014 | patients | Peripheral blood mononuclear cells | Chronic lymphocytic leukemia | Chronic lymphocytic leukemia (CLL) | Targeted therapy | ibrutinib | pre | Malignant cells | -0.300309 | 0.00e+00 |
GSE111014 | patients | Peripheral blood mononuclear cells | Chronic lymphocytic leukemia | Chronic lymphocytic leukemia (CLL) | Targeted therapy | ibrutinib | pre | CD8+ T cells | -0.402561 | 4.13e-10 |
GSE131984_JQ1 | SUM159 cell line | Cell line | Breast cancer | Triple-negative breast cancer (TNBC) | Targeted therapy | JQ1 | NA | Malignant cells | 0.513732 | 0.00e+00 |
GSE131984_JQ1Pac | SUM159 cell line | Cell line | Breast cancer | Triple-negative breast cancer (TNBC) | Targeted therapy | JQ1 + paclitaxel | NA | Malignant cells | 0.641404 | 0.00e+00 |
GSE104987 | MCF7 cell line | Cell line | Breast cancer | ER+ breast cancer | Targeted therapy | KDM5-C70 | NA | Malignant cells | -0.328711 | 1.40e-43 |
GSE108397 | 451Lu cell line | Cell line | Melanoma | Melanoma | Targeted therapy | PLX-4720 | NA | Malignant cells | 0.740152 | 0.00e+00 |
GSE161801_IMiD | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | pomalidomide + dexamethasone OR lenalidomide + dexamethasone | pre | Mono/Macro | -0.416557 | 1.03e-34 |
GSE161801_IMiD | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | pomalidomide + dexamethasone OR lenalidomide + dexamethasone | pre | CD4+ T cells | -0.544869 | 3.67e-32 |
GSE161801_IMiD | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | pomalidomide + dexamethasone OR lenalidomide + dexamethasone | pre | NK cells | -0.581317 | 0.00e+00 |
GSE161801_IMiD | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | pomalidomide + dexamethasone OR lenalidomide + dexamethasone | pre | Malignant cells | -0.358527 | 0.00e+00 |
GSE161801_IMiD | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | pomalidomide + dexamethasone OR lenalidomide + dexamethasone | pre | B cells | -0.524227 | 0.00e+00 |
GSE161801_IMiD | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | pomalidomide + dexamethasone OR lenalidomide + dexamethasone | pre | CD8+ T cells | -0.641408 | 0.00e+00 |
GSE161801_IMiD | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | pomalidomide + dexamethasone OR lenalidomide + dexamethasone | pre | cDCs | -0.545988 | 7.07e-06 |
GSE175716 | PDX | Tumor tissue | Liver cancer | Advanced hepatocellular carcinoma | Targeted therapy | sorafenib | NA | Malignant cells | 1.4027 | 0.00e+00 |
GSE164897_VemCob | A375 cell line | Cell line | Melanoma | BRAFV600E-mutant melanoma | Targeted therapy | vemurafenib + combimetinib | NA | Malignant cells | -0.737828 | 0.00e+00 |
Top |
Expression of TPT1 in the resistant group across all datasets and cell types |
| Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.) |
 |
Top |
Significant ligand-receptor pairs related to TPT1 |
| This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.) |
Top |
Known drug resistance mechanisms of this gene |
| This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information. |
| Gene symbol | Mechanism |
TPT1 | Unusual Activation of Pro-survival Pathway |
| Page: 1 |
Top |
MicroRNAs (miRNA) regulating TPT1 |
| This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.) |
| Gene symbol | miRNA | Score | GeneBank accession |
| TPT1 | hsa-miR-5588-3p | 94.4228 | NM_001286272 |
| TPT1 | hsa-miR-4698 | 93.8095 | NM_001286272 |
| TPT1 | hsa-miR-8063 | 92.4967 | NM_001286272 |
| TPT1 | hsa-miR-1910-5p | 92.0109 | NM_001286272 |
| TPT1 | hsa-miR-455-3p | 92.0109 | NM_001286272 |
| TPT1 | hsa-miR-586 | 91.074 | NM_001286272 |
| TPT1 | hsa-miR-3942-3p | 89.3108 | NM_001286273 |
| TPT1 | hsa-miR-3064-3p | 87.3374 | NM_001286272 |
| TPT1 | hsa-miR-4474-5p | 87.3003 | NM_001286273 |
| TPT1 | hsa-miR-1236-3p | 87.1367 | NM_001286272 |
| TPT1 | hsa-miR-1228-3p | 87.0509 | NM_001286273 |
| TPT1 | hsa-miR-575 | 86.6025 | NM_001286272 |
| TPT1 | hsa-miR-4676-5p | 86.6025 | NM_001286272 |
| TPT1 | hsa-miR-640 | 85.9818 | NM_001286273 |
| TPT1 | hsa-miR-6838-3p | 84.9149 | NM_001286272 |
| TPT1 | hsa-miR-6833-3p | 84.4521 | NM_001286273 |
| TPT1 | hsa-miR-4768-5p | 84.2284 | NM_001286273 |
| TPT1 | hsa-miR-6516-5p | 83.8905 | NM_001286273 |
| TPT1 | hsa-miR-519d-5p | 83.4797 | NM_001286272 |
| TPT1 | hsa-miR-6509-3p | 82.6914 | NM_001286273 |
| TPT1 | hsa-miR-1248 | 81.451 | NM_001286273 |
| TPT1 | hsa-miR-3156-3p | 80.8904 | NM_001286273 |
| Page: 1 |
Top |
Motifs and transcription factors (TFs) regulating TPT1 |
| This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.) |
| Gene symbol | motif | TF_highConf |
| TPT1 | cisbp__M02645 | ETS1 (directAnnotation). |
| TPT1 | taipale_tf_pairs__ETV2_HOXA2_NCCGGAAGTMATTA_CAP_repr | ETV2; HOXA2 (directAnnotation). |
| TPT1 | dbtfbs__GMEB1_K562_ENCSR928KOR_merged_N1 | GMEB1 (directAnnotation). |
| TPT1 | taipale_tf_pairs__ETV2_TCF3_CASSTGNNCCGGAWRYN_CAP_repr | ETV2; TCF3 (directAnnotation). |
| TPT1 | taipale_tf_pairs__HOXB2_ELK3_RSCGGAAGTMRTTA_CAP | ELK3; HOXB2 (directAnnotation). |
| TPT1 | taipale_tf_pairs__ELK1_HOXA1_RCCGGAAGTAATTA_HT | ELK1; HOXA1 (directAnnotation). |
| TPT1 | taipale_tf_pairs__HOXB2_ELF1_SMGGAAGTMRTTA_CAP | ELF1; HOXB2 (directAnnotation). |
| TPT1 | taipale_tf_pairs__ERF_HES7_NCCGGAANNNNNNCACGYGNN_CAP_repr | ERF; HES7 (directAnnotation). |
| TPT1 | metacluster_19.7 | GMEB1; GMEB2 (inferredBy_Orthology). |
| TPT1 | metacluster_111.5 | E4F1; E4F1 (directAnnotation). |
| TPT1 | jaspar__MA1957.1 | ELK1 (directAnnotation). |
| TPT1 | transfac_pro__M05474 | ZNF639 (directAnnotation). |
| TPT1 | taipale_tf_pairs__ERF_CEBPD_RSMGGAANTTGCGYAAN_CAP | CEBPD; ERF (directAnnotation). |
| TPT1 | metacluster_21.4 | HSF1; HSF1; HSF2 (directAnnotation). HSF1; HSF2; HSF4; HSF5; HSFX1; HSFX2; HSFX3; HSFX4; HSFY1; HSFY2 (inferredBy_Orthology). |
| TPT1 | taipale_tf_pairs__FLI1_CEBPB_RNCGGANNTTGCGCAAN_CAP | CEBPB; FLI1 (directAnnotation). |
| TPT1 | metacluster_56.3 | HSF2 (directAnnotation). |
| TPT1 | taipale_tf_pairs__GCM2_ONECUT2_RTRCGGGNNNNNNATCRATN_CAP_repr | GCM2; ONECUT2 (directAnnotation). |
| TPT1 | taipale_cyt_meth__CREB1_NRTGACGTN_eDBD_repr | CREB1 (directAnnotation). |
| TPT1 | kznf__ZNF730_Imbeault2017_RP_RCADE | ZNF730 (directAnnotation). |
| TPT1 | metacluster_111.3 | ATF1; ATF3; CREB1; CREB1; CREB1; CREB1; CREB1; CREM; CREM; CREM; CREM; E4F1; E4F1 (directAnnotation). CREB1; CREB1; CREM; JDP2 (inferredBy_Orthology). |
| TPT1 | jaspar__MA0604.1 | ATF1 (inferredBy_Orthology). |
| TPT1 | kznf__ZNF548_Imbeault2017_RP_RCADE | ZNF548 (directAnnotation). |
| TPT1 | taipale_tf_pairs__ETV5_CEBPD_NSCGGANNTTRCGYAAN_CAP | CEBPD; ETV5 (directAnnotation). |
| TPT1 | taipale_tf_pairs__HOXD12_ETV4_RSCGGAAGTCGTAAAN_CAP | ETV4; HOXD12 (directAnnotation). |
| TPT1 | taipale_tf_pairs__HOXD12_ETV1_RSCGGAAGTNGTAAAN_CAP | ETV1; HOXD12 (directAnnotation). |
| TPT1 | dbtfbs__GMEB2_HepG2_ENCSR745VSQ_merged_N1 | GMEB2 (directAnnotation). |
| TPT1 | transfac_pro__M01861 | ATF1 (directAnnotation). |
| TPT1 | transfac_pro__M05896 | ZNF713 (directAnnotation). |
| TPT1 | taipale_tf_pairs__ETV2_CEBPD_RSCGGANNTTGCGYAAN_CAP_repr | CEBPD; ETV2 (directAnnotation). |
| TPT1 | transfac_public__M00114 | CREB1 (directAnnotation). |
| TPT1 | metacluster_111.4 | ATF1; ATF1; ATF1; ATF1; ATF1; ATF1; ATF2; ATF2; ATF2; ATF2; ATF2; ATF2; ATF2; ATF2; ATF2; ATF2; ATF3; ATF3; ATF3; ATF3; ATF3; ATF4; ATF4; ATF5; ATF6; ATF6B; ATF7; ATF7; ATF7; BATF3; BATF3; CREB1; CREB1; CREB1; CREB1; CREB1; CREB1; CREB1; CREB1; CREB1; CREB1; CREB3; CREB3L4; CREB3L4; CREB5; CREB5; CREB5; CREM; CREM; CREM; CREM; CREM; FOSB; FOSL1; FOSL1; FOSL2; JDP2; JDP2; JDP2; JUN; JUNB; JUNB; JUNB; JUND; JUND; JUND; JUND; JUND; XBP1; XBP1; XBP1; ZNF629 (directAnnotation). ATF1; ATF1; ATF1; ATF2; ATF2; ATF3; ATF6; ATF6B; ATF7; ATF7; ATF7; ATF7-NPFF; ATF7-NPFF; ATF7-NPFF; ATF7-NPFF; BATF; BATF2; BATF3; CREB1; CREB1; CREB3; CREB3L1; CREB3L2; CREB3L3; CREB3L4; CREM; FOS; FOSB; FOSL1; FOSL2; JDP2; JDP2 (inferredBy_Orthology). |
| TPT1 | metacluster_190.8 | ILF2; NFAT5; NFAT5; NFAT5; NFAT5; NFATC1; NFATC2; NFATC3; NFATC4; NFATC4 (directAnnotation). |
| TPT1 | hocomoco__OTX1_HUMAN.H11MO.0.D | OTX1 (directAnnotation). |
| TPT1 | metacluster_131.3 | ZNF436 (inferredBy_Orthology). |
| TPT1 | kznf__ZNF384_Schmitges2016_RCADE | ZNF384 (directAnnotation). |
| TPT1 | metacluster_58.7 | FOS; JUN; NFATC1 (directAnnotation). |
| TPT1 | transfac_pro__M05794 | ZNF621 (directAnnotation). |
| TPT1 | jaspar__MA1125.1 | ZNF384 (directAnnotation). |
| TPT1 | taipale_tf_pairs__GCM1_ETV4_RTGCGGGCGGAAGTR_CAP | ETV4; GCM1 (directAnnotation). |
| TPT1 | hocomoco__GMEB2_HUMAN.H11MO.0.D | GMEB2 (directAnnotation). |
| TPT1 | taipale_tf_pairs__GCM1_ELK1_RTGCGGGCGGAAGTN_CAP_2 | ELK1; GCM1 (directAnnotation). |
| TPT1 | transfac_pro__M06384 | ZNF551 (directAnnotation). |
| TPT1 | taipale_tf_pairs__HOXD12_ETV1_RSCGGAAGTAATAAAN_CAP | ETV1; HOXD12 (directAnnotation). |
| TPT1 | transfac_pro__M04870 | HDAC2 (directAnnotation). |
| TPT1 | metacluster_2.9 | IRF2; IRF2; IRF2; PRDM1; PRDM1 (directAnnotation). PRDM1 (inferredBy_Orthology). |
| TPT1 | swissregulon__hs__HSF2 | HSF2 (directAnnotation). |
| TPT1 | transfac_pro__M06270 | ZNF468 (directAnnotation). |
| TPT1 | metacluster_52.10 | GTF3C2; ZNF436 (directAnnotation). |
| TPT1 | taipale_tf_pairs__PBX4_HOXA10_NTCGTAAATCA_CAP_repr | HOXA10; PBX4 (directAnnotation). |
| TPT1 | homer__ATTGCGCAAC_CEBP | CEBPB (inferredBy_Orthology). |
| Page: 1 2 3 4 5 6 |
Top |
Acts as a transcription factor |
| This table shows that this differential gene acts as a transcription factor. |
Top |
Acts as a drug target |
| This table shows that this differential gene acts as a drug target. |
| Target name | Drug name | Drug ID | Drug type |
| TPT1 | "Calcium citrate" | DB11093 | small molecule |
| TPT1 | "Calcium phosphate dihydrate" | DB14481 | small molecule |
| TPT1 | "Calcium Phosphate" | DB11348 | small molecule |
| Page: 1 |
| 1 | "Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618." |
| 2 | "Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335." |
Copyright 2022-Present -The University of Texas Health Science Center at Houston |